What is the current epidemiology of acute myeloid leukemia in germany?
Best insight from top research papers
The current epidemiology of acute myeloid leukemia (AML) in Germany shows that the disease primarily affects older individuals, with a median age of 72 years at diagnosis. The annual incidence of AML in Germany is around 4,100 cases, and there have been no significant changes in incidence rates over the past decade . The five-year relative survival rate for AML patients in Germany is higher compared to the United States, with an overall rate of 22.8% in Germany and 18.8% in the US. The survival advantage in Germany is particularly pronounced in younger age groups, with five-year survival rates of 64.3% for ages 15-24 and 61.8% for ages 35-44 . Further analysis is needed to identify risk factors for poor outcomes in AML in the US and improve survival rates .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The paper provides an overview of the epidemiology of acute leukemia in Germany, including acute myeloid leukemia (AML). However, it does not specifically mention the current epidemiology of AML in Germany. | |
| The provided paper is about chronic myeloid leukemia (CML), not acute myeloid leukemia (AML). The paper does not provide information on the current epidemiology of AML in Germany. | |
| The paper provides population-level data on survival of patients with acute myeloblastic leukemia (AML) in Germany and the United States, but it does not specifically discuss the current epidemiology of AML in Germany. | |
| The paper provides information on the epidemiology of acute myeloid leukemia (AML) in Germany. It states that AML is the most frequent acute leukemia in adults with an incidence of 3 to 4 per 100,000 persons per year. However, it does not provide specific current epidemiological data for AML in Germany. | |
| The provided paper is about the epidemiology of haemophagocytic lymphohistiocytosis (HLH) in Germany. It does not provide information about the current epidemiology of acute myeloid leukemia in Germany. |
Related Questions
How common is anemia in patients with Acute Myeloid Leukemia?5 answersAnemia is a prevalent issue in patients with various types of leukemia. In Chronic Myeloid Leukemia (CML) patients treated with Imatinib, the prevalence of anemia was found to be 34%. On the other hand, in patients with Acute Lymphoblastic Leukemia (ALL) on maintenance therapy, anemia was observed in 80% of cases, with specific micronutrient deficiencies like folate and vitamin B12 contributing significantly to the anemia. Additionally, autoimmune hemolytic anemia (AIHA) can also be a concern in leukemia patients, characterized by autoantibodies targeting red blood cells. Therefore, anemia is a common finding in leukemia patients, necessitating close monitoring of hemoglobin levels and timely identification and correction of underlying causes to enhance treatment outcomes.
What is the current 5-year prevalence of cancer in Europe?4 answersThe current 5-year prevalence of cancer in Europe is estimated to be 28.8 million in 2008, with variations across different regions and countries. Cancer remains a significant health concern in Europe, with almost 1.2 million cancer-related deaths in EU countries in 2019, representing over a quarter of all deaths. Geographically, cancer burden and survival rates differ within Europe, with higher survival rates observed in northern and central Europe compared to the UK and eastern Europe. Factors such as obesity and tobacco use are key drivers of cancer incidence, mortality, and survival trends across Europe, with varying patterns observed since the mid-1990s. Efforts like the Europe’s Beating Cancer Plan aim to reduce the burden of cancer and address inequalities in cancer care within and between European countries.
What is the current data on human CMV (Cytomegalovirus) prevalence in Germany?4 answersThe prevalence of human cytomegalovirus (CMV) in Germany varies among different populations. In pregnant women, studies show low awareness and testing rates, with only around 32% undergoing serological screening. Among transplant recipients, CMV infection rates were found to be significant, affecting 29.2% of allogeneic hematopoietic stem cell transplant (allo-HSCT) patients and 16.8% of solid organ transplant (SOT) patients within the first year post-transplantation. In the general population, the overall CMV seroprevalence in an urban region of Germany has shown a non-significant decline from 57.25% in 1998-2008 to 56.48% in 2009-2018, with variations observed based on gender and specific risk groups like HIV patients and women of childbearing age.
What is the prevalence of COVID-19 in Germany?3 answersThe prevalence of COVID-19 in Germany varied across the studies. One study found a prevalence of 13.8% in symptomatic patients tested in general practices from March 2020 to March 2021. Another study estimated a cumulated prevalence of about 3% across all age bands during the first COVID-19 wave. A pre-vaccine seroprevalence study reported a seroprevalence of 1.7% when adjusting for antibody decay, and an overall infection prevalence of 2.1% including self-reports. However, it is important to note that these studies may not capture the true prevalence of COVID-19 in the entire population, as they focused on specific groups or time periods.
How many people live in Germany?5 answersGermany is home to approximately 80.8 million people.
Do people in germany know about the rate of misscariages?3 answersThe prevalence and incidence of miscarriages in Germany are not directly addressed in the provided abstracts. The abstracts discuss various topics such as palliative care patients and mortality rates, monitoring networks for radioactivity, nonpaternity rates, economic costs associated with absenteeism, and causes of severe visual impairment and blindness. None of these abstracts provide information about the knowledge or awareness of the general population in Germany regarding the rate of miscarriages.